You are here

Press Release Archive

 
- Pfizer’s Oncology Business Unit Appoints Senior Executive to Head U.S. Region

(BUSINESS WIRE)--Pfizer Inc announced today the appointment of Elizabeth Barrett to Regional President, U.S. for its Oncology Business Unit where she will lead sales, field operations, and marketing. Ms. Barrett possesses over 25 years of management expertise and a proven track record in building profitable organizations, working in multi-national companies with international experience and launching and expanding new businesses.

 
- Pfizer-Sponsored Prescription Savings Program - Together Rx Access® - Expands Eligibility Criteria in Response to Challenging Economic Times

(BUSINESS WIRE)--Pfizer Inc announced today that Together Rx Access®, a prescription savings program sponsored by Pfizer along with several other leading pharmaceutical companies, has expanded the program’s eligibility income levels to help even more uninsured individuals and families save on the medicines they need to stay healthy and to manage chronic conditions. Under the new income levels, nearly 90 percent of uninsured Americans

 
- U.S. Patent & Trademark Office Grants Reissue Patent Relating to Lipitor

(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has granted reissue patent RE40667, relating to Lipitor. The company had applied for the reissue patent in January 2007, in order to correct a technical defect in the ‘995 enantiomer patent for atorvastatin calcium, the salt form of atorvastatin sold as Lipitor. On January 6, 2009, the company announced that the U.S. Patent & Trademark Office had issued

 
- Wide-Reaching Global Survey Reveals Majority of Women Living with Metastatic Breast Cancer Desire Increased Public Attention

(BUSINESS WIRE)--A new global survey of 950 women living with metastatic breast cancer (MBC) in nine countries (the United Kingdom, France, Spain, Belgium, Poland, the United States, Argentina, Egypt and Mexico) found that despite the negative impact of their disease, a majority still enjoy life and desire public attention that recognizes their unique experiences. Based on the survey results, the international committee of experts overseeing

 
- Pfizer Invites Public to View and Listen to Webcast of Investor Breakfast at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a discussion with members of Pfizer’s leadership team at an investor breakfast at the Cowen and Company 29th Annual Healthcare Conference on Wednesday, March 18, 2009 at 7:00 a.m. Eastern Daylight Saving Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Pfizer Investor

 
- Pfizer and Bausch & Lomb to Co-Promote Products for the Treatment of Ophthalmic Conditions

(BUSINESS WIRE)--Pfizer Inc and Bausch & Lomb announced today a co-promotion agreement involving both companies’ prescription ophthalmic pharmaceuticals in the United States. The agreement will allow both companies to greatly increase the level of eye care industry support for these important medications that treat serious ophthalmic conditions. The five-year agreement includes Pfizer’s Xalatan

 
- Pfizer Expands Portfolio of Generic Medicines in the U.S. and Europe Through Licensing Agreements with Aurobindo

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today that it has entered into a series of agreements with Aurobindo Pharma Ltd., a pharmaceutical company based in India, to commercialize medicines that are no longer patent protected, and have lost market exclusivity in the United States and Europe, further progressing its Established Products Business Unit strategy. Pfizer’s Established Products Business Unit, focused on the

 
- Pfizer Discontinues Development of Two Phase 3 Compounds

(BUSINESS WIRE)--Pfizer Inc announced today that, following a review of the development and commercial portfolios in the Primary Care Business Unit, it is terminating Phase 3 development programs for the investigational compounds esreboxetine for fibromyalgia and PD 332,334 for generalized anxiety disorder (GAD). The decision to terminate these programs will enable the Business Unit to allocate additional resources to higher-

 
- Pfizer to Publicly Disclose Payments to U.S. Physicians, Healthcare Professionals and Clinical Investigators

(BUSINESS WIRE)--Pfizer Inc today announced its plans to make publicly available its compensation of U.S. healthcare professionals for consulting, speaking engagements and clinical trials. The disclosure will include payments made to practicing U.S. physicians and other healthcare providers, as well as principal investigators, major academic institutions and research sites for clinical research. This makes Pfizer the first biopharmaceutical

 
- Pfizer and The Pfizer Foundation Recognize "World Cancer Day" Award $7 Million in Grants to Support Global Cancer Control Efforts

(BUSINESS WIRE)--Pfizer Inc and The Pfizer Foundation announced today, on “World Cancer Day”, that they have awarded $7 million in 2009 to help 13 non-governmental organizations (NGOs) focus on improving both treatment and prevention for cancer patients, through its Global Health Partnerships grants program (GHP). Since 2007, 29 Global Health Partnerships grants have been awarded to NGOs working in more than 46 countries around

 
- Pfizer’s Sutent is Recommended as First-Line Treatment for Kidney Cancer Patients by British Health Agency

(BUSINESS WIRE)--Pfizer Inc said today that the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) has issued its final appraisal document (FAD) recommending the use of Sutent (sunitinib malate) as a first-line treatment for patients with metastatic renal cell carcinoma mRCC (advanced kidney cancer). According to NICE, “Sutent provided a step-change in the first-line treatment of advanced and/or metastatic

 
- Lipitor Significantly Reduced hsCRP Levels in Patients with Stable Coronary Artery Disease, According to New Study

(BUSINESS WIRE)--Patients treated with Lipitor® (atorvastatin calcium) 80 mg had a significant 55 percent reduction in levels of high-sensitivity C-reactive protein (hsCRP), while those taking Lipitor 10 mg had a significant 21 percent reduction in hsCRP levels at the end of 26 weeks compared to baseline, according to the results from the primary endpoint of a new study. Patients in this study had stable coronary artery disease, normal

 
- Pfizer Discontinues Global Phase III Trial of Axitinib for Futility in Advanced Pancreatic Cancer

(BUSINESS WIRE)--Pfizer Inc announced today the discontinuation of a Phase III study of its investigational agent axitinib for the treatment of advanced pancreatic cancer. Based on an interim analysis, an independent Data Safety Monitoring Board (DSMB) found no evidence of improvement in the primary endpoint of survival in patients treated with axitinib and gemcitabine, compared to gemcitabine alone, the current standard of care for patients

 
- Geodon Proven Effective as Adjunctive Maintenance Treatment of Bipolar Disorder

(BUSINESS WIRE)--Pfizer's Geodon (ziprasidone HCl) was an effective and generally well-tolerated adjunctive treatment to mood stabilizers for the maintenance treatment of bipolar disorder, according to a new study presented earlier this week at the European Psychiatric Association's European Congress of Psychiatry. Ziprasidone is available in Europe and other markets under the trade name Zeldox. “Patients with bipolar disorder

 
- Pfizer Invites Public to Listen to Audio-Only Webcast of January 27 Investor Luncheon

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to an audio-only webcast of a discussion with the Pfizer leadership team at an investor luncheon on Tuesday, January 27, 2009 at 12:30 p.m. Eastern Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Pfizer Investor Luncheon” link in the Investor Presentations tab on our homepage. Information

 
- MEDIA ADVISORY: Pfizer and Wyeth to Host Live Press Conference in New York

(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) today announced that they will be holding a live press conference to discuss today’s announcement that Pfizer will acquire Wyeth. The executives will make remarks followed by Q&A. When: 10:00 AM EST Monday

 
- Pfizer Reports Fourth-Quarter and Full-Year 2008 Results and 2009 Financial Guidance

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE): ($ in millions, except per share amounts) Fourth-Quarter Full-Year 2008 2007

 
- Pfizer Receives FDA Complete Response Letter for Lasofoxifene

(BUSINESS WIRE)--Pfizer Inc said today it has received a complete response letter from the U.S. Food and Drug Administration (FDA) asking for additional information on the company’s application for lasofoxifene. The investigational compound is currently under review for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. Pfizer is reviewing the letter and will work with FDA to determine the

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.